Deerfield Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Deerfield Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,667,000	Closed	-$18M	–	121
2015 Q4	$18M	Hold	1,667,000	–	–	0.73%	49
2015 Q3	$11.5M	Buy	+1,667,000	New	+$13.6M	0.45%	70
2015 Q2	–	Sell	-2,810,164	Closed	-$27.7M	–	142
2015 Q1	$27.7M	Sell	2,810,164 -110,136	-4%	-$1.38M	0.9%	31
2014 Q4	$35.8M	Buy	+2,920,300	New	+$35.7M	1.29%	25
2014 Q3	–	Sell	-12,500	Closed	-$95K	–	153
2014 Q2	$95K	Sell	12,500 -80,304	-87%	-$320K	﹤0.01%	127
2014 Q1	$305K	Buy	+92,804	New	+$325K	0.01%	123
2013 Q3	–	Sell	-1,629,833	Closed	-$13.3M	–	135
2013 Q2	$13.3M	Buy	+1,629,833	New	+$12.4M	0.63%	56

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's ACHN Position: Q1 2016 in Review

Deerfield Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2016, closing a stake of 1,667,000 shares — an estimated $18M sold.

Deerfield Management first reported a position in ACHN in Q2 2013 and held it in 7 quarters. The position peaked at $35.8M in Q4 2014. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

Deerfield Management reported no remaining Achillion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Deerfield Management sold 1,667,000 Achillion Pharmaceuticals shares in Q1 2016, an estimated $18M.
Deerfield Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Deerfield Management's Achillion Pharmaceuticals position peaked at $35.8M in Q4 2014.
153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.